

Schaffhausen, June 25, 2012

**Announcement according to Art. 9 and Art. 21 SESTO-FINMA
Disclosure of shareholdings**

Pursuant to Art. 9 and Art. 21 SESTO-FINMA, The Bank of New York Mellon Corporation, New York, USA, has announced to BB Biotech AG, Schaffhausen, Switzerland, the change to the composition of the Group due to the removal of BNY Mellon Service Kapitalanlage-Gesellschaft mbH as direct holder and The Bank of New York Mellon, BNY International Financing Corporation, The Bank of New York Mellon SA/NV and BNY Mellon Asset Servicing GmbH as indirect holders of registered shares BB Biotech AG (ISIN CH0038389992).

The Bank of New York Mellon Corporation, New York, USA, held 1 229 389 voting rights (9.46% of the proportion of voting rights) as per June 18, 2012, directly or indirectly by the companies listed below:

Direct Holders:

- Newton Investment Management AG Ltd., London, England

Indirect Holders:

- MBC Investments Corporation, Greenville, Delaware, USA
- Mellon International Holdings S.a.r.l., Luxembourg
- BNY Mellon International Asset Management Group Limited, London, England
- Newton Management Limited, London, England

For further information, please contact:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Thomas Egger, Tel. +41 44 267 67 09, teq@bellevue.ch
www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with CHF 1.2 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.